Post by Psychocreature on Mar 1, 2024 23:37:15 GMT -5
Cases of myocarditis and pericarditis have rarely been observed after COVID-19 vaccination in the United States and evidence from multiple vaccine safety monitoring systems in the United States and around the globe supports a causal association between mRNA COVID-19 vaccines (i.e., Moderna or Pfizer-BioNTech) and myocarditis and pericarditis.
Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining outside the heart; myopericarditis is when both myocarditis and pericarditis occur at the same time. In these conditions, inflammation occurs in response to an infection or some other trigger. CDC has published case definitions for myocarditis and pericarditis.
Though cases of myocarditis and pericarditis are rare, when cases have occurred, they have most frequently been seen in adolescent and young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine; however, cases have also been observed in females, in other age groups, and after other doses.
The severity of myocarditis and pericarditis cases can vary; most patients with myocarditis after mRNA COVID-19 vaccination have experienced resolution of symptoms by hospital discharge. CDC has published studies with clinical information about myocarditis and pericarditis after COVID-19 vaccination.
Data from the clinical trials of the Novavax COVID-19 vaccine and post-authorization vaccine safety monitoring outside the United States suggest an increased risk of myocarditis and pericarditis following Novavax vaccination.
www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining outside the heart; myopericarditis is when both myocarditis and pericarditis occur at the same time. In these conditions, inflammation occurs in response to an infection or some other trigger. CDC has published case definitions for myocarditis and pericarditis.
Though cases of myocarditis and pericarditis are rare, when cases have occurred, they have most frequently been seen in adolescent and young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine; however, cases have also been observed in females, in other age groups, and after other doses.
The severity of myocarditis and pericarditis cases can vary; most patients with myocarditis after mRNA COVID-19 vaccination have experienced resolution of symptoms by hospital discharge. CDC has published studies with clinical information about myocarditis and pericarditis after COVID-19 vaccination.
Data from the clinical trials of the Novavax COVID-19 vaccine and post-authorization vaccine safety monitoring outside the United States suggest an increased risk of myocarditis and pericarditis following Novavax vaccination.
www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html